Načítá se...
An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
Certolizumab pegol (CZP) is a pegylated humanized tumor necrosis factor-α inhibitor (TNFi) approved for the treatment of psoriatic arthritis (PsA) in Europe, the USA, and Latin American countries. CZP neutralizes TNF-α at its soluble and membrane portions. Due to the lack of Fc region, it does not i...
Uloženo v:
| Vydáno v: | Open Access Rheumatol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5098767/ https://ncbi.nlm.nih.gov/pubmed/27843368 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OARRR.S56837 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|